Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.66 |
| ▸ | RGS12 | O14924 | 3/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesulergine SCHEMBL11415354 | 1.00 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL292175 | 1.00 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL29408582 | 1.00 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL1321023 | 0.99 | HTR2B (0.98) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL677489 | 0.98 | HTR2B (0.96) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670412 | 0.88 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670405 | 0.88 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670418 | 0.88 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Disulergine SCHEMBL11408974 | 0.81 | HTR7 (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Disulergine SCHEMBL11408971 | 0.81 | HTR7 (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4515950-A | Process for the isomerization of ergovine derivatives | SANDOZ LTD. (CH) | 1985-05-07 | — | — | US | claimed |
| EP-0048695-A1 | Isomerisation process of ergoline derivatives | SANDOZ AG (CH) | 1982-03-31 | — | — | EP | claimed |
| US-4225605-A | Ergolene or ergoline compounds for treating congestive heart failure | SANDOZ LTD. (CH) | 1980-09-30 | — | — | US | claimed |
| US-8877755-B2 | Dopamine-agonist combination therapy for improving sleep quality | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100004251-A1 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality | SEPRACOR INC. (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050267176-A1 | Dopamine-agonist combination therapy for improving sleep quality | SEPRACOR INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-4515950-A | Process for the isomerization of ergovine derivatives | SANDOZ LTD. (CH) | 1985-05-07 | — | — | US | disclosed |
| EP-0048695-A1 | Isomerisation process of ergoline derivatives | SANDOZ AG (CH) | 1982-03-31 | — | — | EP | disclosed |
| US-4225605-A | Ergolene or ergoline compounds for treating congestive heart failure | SANDOZ LTD. (CH) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267176-A1 | Dopamine-agonist combination therapy for improving sleep quality | DRD2, DRD1, HTR5A | HTR2B 38/4885HTR2A 14/4885ALDH1A1 1834/4885 |
| US-20100004251-A1 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality | DRD2, DRD1, DRD3 | HTR2B 40/4885HTR2A 14/4885ALDH1A1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.